Zevra Therapeutics (NASDAQ:ZVRA) Receives “Overweight” Rating from Cantor Fitzgerald

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports.

ZVRA has been the topic of a number of other reports. Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. JMP Securities initiated coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Roth Mkm upped their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, Maxim Group upped their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $20.83.

Zevra Therapeutics Trading Up 3.0 %

Shares of ZVRA opened at $8.16 on Friday. The business’s 50-day moving average price is $7.44 and its 200 day moving average price is $5.87. The stock has a market capitalization of $429.38 million, a P/E ratio of -4.86 and a beta of 1.94. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same period in the prior year, the business posted ($0.15) EPS. Analysts expect that Zevra Therapeutics will post -1.63 earnings per share for the current year.

Insider Activity at Zevra Therapeutics

In related news, Director Thomas Anderson acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now owns 20,000 shares of the company’s stock, valued at $136,200. This trade represents a 100.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of ZVRA. Virtu Financial LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter worth about $177,000. Mystic Asset Management Inc. increased its holdings in shares of Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock worth $1,545,000 after acquiring an additional 35,514 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in shares of Zevra Therapeutics by 11.0% in the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after acquiring an additional 42,766 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after acquiring an additional 58,866 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Zevra Therapeutics in the first quarter worth about $64,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.